Related Experiment Video
Updated: May 6, 2026
Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples
Published on: July 28, 2016
Increased myeloperoxidase plasma levels in patients with Alzheimer's disease
Stergios Tzikas1, Dennis Schlak2, Kateryna Sopova3
1Department of Cardiology, Ruhr University Bochum, Marienhospital Herne, Herne, Germany.
Background:
Increasing evidence supports the role of cardiovascular risk factors in the development of Alzheimer's disease (AD).
Objective:
In the present pilot study, we investigated plasma concentrations of myeloperoxidase (MPO) and its possible association with plasma amyloid-β (Aβ)1-42/1-40 ratio in AD patients and elderly healthy controls.
Methods:
The study sample included 28 AD patients and 27 elderly individuals with a normal cognitive status as a control group. The Mini-Mental Status Examination was used to determine the global cognition. MPO, Aβ1-40, and Aβ1-42 plasma concentrations were measured by enzyme linked immunoabsorbent assays.
Results:
AD patients showed significantly higher plasma concentrations of MPO in comparison to healthy elderly controls (AD versus healthy elderly controls (mean ± SD): 132.8 ± 114.8 ng/mL versus 55.0 ± 42.6 ng/mL; p = 0.002). MPO plasma concentrations showed a significant positive correlation in the whole sample with the presence of AD (ρ = 0.428, p < 0.001) and its stage (ρ = 0.331; p = 0.013) as well as with plasma concentrations of Aβ1-42 (ρ = 0.406; p = 0.004) and Aβ1-42/1-40 ratio (ρ = 0.354; p = 0.013). In a binary logistic regression model, plasma MPO concentrations were independently associated with the presence of AD (p = 0.014).
Conclusion:
AD patients showed significantly increased plasma levels of MPO, which could be an important molecular link between atherosclerosis and AD. Further studies should evaluate whether MPO may also be a useful biomarker and potential new treatment target in AD.
Insights
Plasma myeloperoxidase (MPO) levels are significantly higher in Alzheimer's disease (AD) patients, suggesting MPO may link cardiovascular health and AD progression. This finding highlights MPO as a potential biomarker for AD.
Area of Science:
- Neurology
- Biochemistry
- Cardiovascular Research
Background:
- Cardiovascular risk factors are increasingly implicated in Alzheimer's disease (AD) pathogenesis.
- Investigating molecular links between cardiovascular health and AD is crucial for understanding disease mechanisms.
Purpose of the Study:
- To examine plasma myeloperoxidase (MPO) concentrations in AD patients compared to healthy controls.
- To assess the association between plasma MPO levels and the plasma amyloid-beta (Aβ)1-42/1-40 ratio in AD.
Main Methods:
- Pilot study involving 28 AD patients and 27 cognitively normal elderly controls.
- Global cognition assessed using the Mini-Mental Status Examination.
- Plasma concentrations of MPO, Aβ1-40, and Aβ1-42 measured via enzyme-linked immunosorbent assays.
Main Results:
- AD patients exhibited significantly elevated plasma MPO levels compared to controls (132.8 vs. 55.0 ng/mL).
- Plasma MPO positively correlated with AD presence, disease stage, Aβ1-42 levels, and the Aβ1-42/1-40 ratio.
- MPO plasma concentrations were independently associated with the presence of AD in logistic regression analysis.
Conclusions:
- Elevated plasma MPO in AD patients suggests a potential molecular link between atherosclerosis and Alzheimer's disease.
- Myeloperoxidase may serve as a valuable biomarker for AD.
- MPO warrants further investigation as a potential therapeutic target for Alzheimer's disease.
More Related Videos
Related Concept Videos
01:29Alzheimer Disease l: Introduction
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:23Alzheimer Disease ll: Pathophysiology